Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and ...
Could this news trigger short-term volatility or a sustained price movement in Clearmind's stock?
What are the projected costs and funding requirements for advancing this therapy through Phase 2 and Phase 3 trials?
How does this development compare to similar pipelines of competitors in the CNS and metabolic space?
18 days ago